Catalyst Pharmaceuticals Newsroom

Stephens Initiates Catalyst Pharmaceuticals(CPRX.US) With Buy Rating, Announces Target Price $35

Moomoo NewsNov 19 03:36 ET

Catalyst Pharmaceuticals Analyst Ratings

BenzingaNov 18 10:29 ET

Stephens & Co. Initiates Coverage On Catalyst Pharmaceuticals With Overweight Rating, Announces Price Target of $35

BenzingaNov 18 10:29 ET

Truist Financial Maintains Catalyst Pharmaceuticals(CPRX.US) With Buy Rating, Announces Target Price $36

Moomoo NewsNov 11 07:34 ET

BofA Securities Maintains Catalyst Pharmaceuticals(CPRX.US) With Buy Rating

Moomoo NewsNov 8 10:37 ET

Oppenheimer Maintains Catalyst Pharmaceuticals(CPRX.US) With Buy Rating, Maintains Target Price $29

Moomoo NewsNov 8 09:38 ET

Catalyst Pharmaceuticals Analyst Ratings

BenzingaNov 8 08:16 ET

H.C. Wainwright Maintains Catalyst Pharmaceuticals(CPRX.US) With Buy Rating, Maintains Target Price $30

Moomoo NewsNov 8 07:31 ET

Truist Financial Maintains Catalyst Pharmaceuticals(CPRX.US) With Buy Rating

Moomoo NewsNov 7 09:31 ET

Citi Maintains Catalyst Pharmaceuticals(CPRX.US) With Buy Rating, Maintains Target Price $31

Moomoo NewsNov 7 06:33 ET

BofA Securities Maintains Catalyst Pharmaceuticals(CPRX.US) With Buy Rating, Announces Target Price $27

Moomoo NewsOct 18 05:33 ET

The Latest Analyst Ratings For Catalyst Pharmaceuticals

BenzingaAug 12 09:03 ET

Catalyst Pharmaceuticals Analyst Ratings

BenzingaAug 9 09:13 ET

Truist Adjusts Price Target on Catalyst Pharmaceuticals to $30 From $25, Maintains Buy Rating

MT NewswiresAug 9 05:34 ET

Catalyst Pharmaceuticals Analyst Ratings

BenzingaJun 6 10:24 ET

Catalyst Pharmaceuticals Analyst Ratings

BenzingaJun 3 06:28 ET

Catalyst Pharmaceuticals Analyst Ratings

BenzingaMay 10 08:12 ET

Catalyst Pharmaceuticals Analyst Ratings

BenzingaMar 27 07:37 ET

Catalyst Pharmaceuticals Analyst Ratings

BenzingaMar 22 14:00 ET

Cantor Fitzgerald Reiterates Overweight on Catalyst Pharmaceuticals, Maintains $34 Price Target

BenzingaMar 22 14:00 ET